Skip to main content
. Author manuscript; available in PMC: 2011 Mar 18.
Published in final edited form as: Cancer Biol Ther. 2008 Oct 9;7(10):1607–1618. doi: 10.4161/cbt.7.10.6584

Figure 2.

Figure 2

Effect of 13-cis retinoic acid and/or dcAMP/IBMX on the proliferation of SKRC06 and SKRC39. Cells were cultured in triplicate wells for six days in the presence of the indicated drug (s). Drugs and medium were changed and replaced on day three. On day six, cells were counted and the average number of cells was compared to the average number of cells in untreated wells. Data are represented as number of cells in treated wells/number of cells in control wells × 100%. All data are from three independent experiments, and each treatment within an experiment was performed in triplicate. SKRC06 (A) and SKRC39 (B) cells were cultured for six days in the presence of: cRA (1 μM) alone; or dibutyryl cAMP (dbcAMP) (250 μM) + 3-isobutyl-1-methylxanthine (IBMX) (100 μM); cRA (1 μM) or + dbcAMP (250 μM) + IBMX (100 μM).